Vaxxas Announces Appointment of Dan Devine as Chief Business Officer and General Counsel
Retrieved on:
Wednesday, April 13, 2022
Oncology, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, IIF, Patri Friedman, Biotechnology, Dan, COVID-19, Refrigeration, Time, NASDAQ, Transport, Wall Street, General counsel, Biomedical Advanced Research and Development Authority, Infection, Growth, Efficiency, Vaccination, University, Development, Vaccine, Skin, Temperature, Innovation, Australian Securities Exchange, Safety, BARDA, Multimedia, Industry, Pharmaceutical industry, Fine chemical, Pfizer, Mesoblast
Dan Devine joins the company as Chief Business Officer and General Counsel.
Key Points:
- Dan Devine joins the company as Chief Business Officer and General Counsel.
- Over his career, Dan has led or supported the negotiation of over 50 M&A, licensing, financing, and other business development collaborations.
- "Im very excited to join Vaxxas at this critical juncture, and I look forward to helping David and the rest of our team achieve our ambitious growth goals, said Dan Devine, Chief Business Officer and General Counsel of Vaxxas.
- As Chief Business Officer and General Counsel, Dan will report directly to Vaxxas CEO David Hoey and has been appointed as Executive Vice President.